<a href="https://laohu8.com/S/IDYA">IDEAYA Biosciences</a> reports Q3 cash and securities of $1.14 billion
IDEAYA Biosciences Inc. reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2025, up from $991.9 million on June 30, 2025. The increase was primarily due to a $210 million upfront payment from Servier under an exclusive license agreement for darovasertib outside the United States. For the third quarter ended September 30, 2025, collaboration revenue totaled $207.8 million, compared to zero in the previous quarter. Under the Servier agreement, IDEAYA is eligible for up to $100 million in regulatory milestone payments, up to $220 million in commercial milestone payments, and double-digit royalties on net sales outside the United States. IDEAYA retains all rights to darovasertib in the United States and will share development costs with Servier. As of September 30, 2025, $143.1 million in research and development service obligations remain to be recognized as collaboration revenue. The company expects its current funds to support operations into 2030.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF14392) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.